Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings

Trial Profile

Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Allergic rhinitis; Grass pollen hypersensitivity
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GRAAL
  • Sponsors ALK-Abello
  • Most Recent Events

    • 16 Sep 2011 ClinicalTrials.gov record identified as an additional source, and actual patient numbers, lead investigator, and ALK Abello A/S added
    • 16 Sep 2011 Status changed from recruiting to completed, as reported in the NCT record
    • 27 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top